Introduction to Novel Antitubercular

Moreover, the molecular docking study of template compound 23j provides new insight into the discovery of novel antitubercular agents targeting DprE1.

BACKGROUND AND PURPOSE Translational efforts in the evaluation of novel antitubercular drugs demand better integration of pharmacokinetic-pharmacodynamic data arising from preclinical protocols.

These interesting results warrant further investigation, which may allow identification of novel antitubercular candidates based on this scaffold.

The search for novel antitubercular chemotherapeutics from underexplored natural sources is therefore of paramount importance.

Furthermore, in the pathogen Mycobacterium tuberculosis, the distribution of G4 motifs and their potential role in the regulation of gene transcription advocate for the use of G4 ligands to develop novel antitubercular therapies.

Hence, in our pursuit of developing novel antitubercular compounds, we are reporting the e-Pharmacophore-based design of DprE1 (decaprenylphosphoryl-ribose 2′-oxidase) inhibitors.

tb) are evolving at an alarming rate, and this indicates the urgent need for the development of novel antitubercular drugs.

Novel antitubercular drugs can be developed by identifying diversiform targets in M.

We believe that this study provides an important initial guidance to medicinal chemists and biochemists to synthesize and test an enriched set of compounds that have the potential to inhibit Mtb USP (Rv1636), thereby aiding the development of novel antitubercular lead candidates.

Extensive biological and physicochemical profiling of this series revealed first structure-activity relationships and set the basis for further optimization and development of this novel antitubercular scaffold.

The present study assessed a novel antitubercular mechanism of of galangal through M.

This review provides an update on the progress of these novel antitubercular agents.

Employing circular dichroism (CD) and UV/VIS absorption spectroscopic methods, we demonstrated and evaluated the AAG binding properties of novel antitubercular drug candidates developed against sensitive and multidrug-resistant strains of M.

Thiosemicarbazide derivative 8n is a candidate for the development of novel antitubercular agents.

1,3,5-Oxadiazole derivatives 1c-e are candidates for the development of novel antitubercular agents.

Conventional treatments to combat the tuberculosis (TB) epidemic are falling short, thus encouraging the search for novel antitubercular drugs acting on unexplored molecular targets.

This newly developed drug screening assay offers an easy, safe, image based high content screening tool to search for novel antitubercular inhibitors against both active and dormant state intracellular mycobacteria.

, ability to grow and multiply inside macrophages and to induce delayed hypersensitivity reactions) and to the emergence and spread of multidrug and extended-drug resistant Mycobacterium tuberculosis strains, correlated with the paucity of novel antitubercular drugs, the objectives of decreasing of incidence, prevalence and mortality rates, and to successfully detect and treat TB are threatened.